{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-040539","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.239380+00:00","generated_at":"2026-05-17T00:13:02.268865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ADMA Q3 revenue $134.2M (+12% YoY); raises FY25 revenue guidance to $510M+, FY26 to $630M+","bullets":["GAAP net income $36.4M (+1% YoY); adjusted EBITDA $58.7M (+29% YoY).","Revenue guidance raised: FY25 to ≥$510M (from >$500M); FY26 to ≥$630M (from >$625M).","Adj EBITDA guidance: FY25 reaffirmed at $235M; FY26 raised to >$355M (from >$340M).","FDA lot release of first yield-enhanced batches; gross margin expansion expected from Q4 2025.","Record ASCENIV demand; real-world data shows >50% infection reduction (2.1→0.9/year)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-040539","json":"https://secwatch.observer/filing/0001140361-25-040539.json","markdown":"https://secwatch.observer/filing/0001140361-25-040539.md","text":"https://secwatch.observer/filing/0001140361-25-040539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/0001140361-25-040539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125040539/ef20058354_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:13:02.268865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}